Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies

Overview of attention for article published in Nature Communications, November 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 12 news outlets
twitter: 10 X users

patent: 3 patents
facebook: 1 Facebook page

Citations

dimensions_citation: 35 Dimensions

Readers on

mendeley: 46 Mendeley

Summary News X Patents Facebook Dimensions citations

So far, Altmetric has seen 3 patents that reference this research output.

RECOMBINANT MVA VIRUSES FOR INTRAPERITONEAL ADMINISTRATION FOR TREATING CANCER

Application WO-2023118508-A1

World Intellectual Property Organisation (WIPO)

RECOMBINANT MVA VIRUSES FOR INTRATUMORAL AND/OR INTRAVENOUS ADMINISTRATION FOR TREATING…

Application WO-2021099586-A1

World Intellectual Property Organisation (WIPO)

MEDICAL USES OF 4-1BBL ADJUVANTED RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA)

Application WO-2021099572-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.